Abstract
Controversy still surrounds the recommendation for performing sentinel node biopsy (SLNB) in patients with primary melanoma 1mm or greater in thickness, but why? In the absence of widespread, metastatic disease, nodal status is the single most important prognostic factor which determines likelihood of survival. It allows early therapeutic removal of micrometastatic lymph node disease and identifies patients who are eligible for Interferon alfa-2b adjuvant therapy. SLNB is a requirement for current clinical trials.
| Original language | English (US) |
|---|---|
| Journal | Dermatology Online Journal |
| Volume | 7 |
| Issue number | 2 |
| State | Published - 2001 |
ASJC Scopus subject areas
- Dermatology
Fingerprint Dive into the research topics of 'Still debating sentinel lymph node biopsy?'. Together they form a unique fingerprint.
Cite this
Burrall, B. A., & Khatri, V. (2001). Still debating sentinel lymph node biopsy? Dermatology Online Journal, 7(2).